| mRNA肿瘤疫苗非病毒递送系统研究进展 |
| 投稿时间：2024-10-21 修订日期：2024-11-18 点此下载全文 |
| 引用本文：周娇,郑建雨,王思真,杨峰.mRNA肿瘤疫苗非病毒递送系统研究进展[J].药学实践杂志,2025,43(3):109~116 |
| 摘要点击次数: 35 |
| 全文下载次数: 79 |
|
| 基金项目:国家自然科学基金（82473891）；基础医学创新课题（JCKFKT-ZD-001） |
|
| 中文摘要:2020年底，FDA紧急批准了两种mRNA疫苗（BNT162b2和mRNA-1273），为应对COVID-19大流行提供了重要支撑。这些基于非病毒载体的COVID-19疫苗取得的巨大成功，推动了mRNA疫苗在肿瘤等疾病治疗领域的研究和应用。与基于病毒的递送系统相比，非病毒载体在生物安全性和多功能性方面具有重大优势。因此，非病毒载体已成为mRNA肿瘤疫苗开发的研究热点。本文重点介绍了非病毒载体的最新研发进展，包括脂质纳米颗粒、聚合物、肽类和无机材料等。此外，本文还概述了mRNA肿瘤疫苗临床试验的最新进展并讨论了非病毒载体在mRNA肿瘤疫苗临床转化面临的挑战以及未来的前景。 |
| 中文关键词:非病毒载体 mRNA疫苗 肿瘤疫苗 免疫治疗 |
| |
| Progress on mRNA tumor vaccine with non-viral delivery system |
|
|
| Abstract:At the end of 2020, the FDA issued emergency use authorization for two mRNA vaccines（BNT162b2 and mRNA-1273）, which had provided important support in the response to the COVID-19 pandemic. The great success of these COVID-19 vaccines based on non-viral vectors has promoted the research and application of mRNA vaccines in the treatment of diseases such as tumors. Compared with virus-based delivery systems, non-viral carriers have significant advantages in biological safety and versatility. Therefore, non-viral vectors have become a research hotshot for mRNA tumor vaccines. In this paper, the latest research progress on lipid nanoparticles, polymers, peptides and inorganic materials were introduced. In addition, recent clinical trials of mRNA tumor vaccines were reviewed and the challenges and prospects of non-viral vectors in clinical transformation of mRNA tumor vaccines were discussed. |
| keywords:non-viral vectors mRNA vaccine tumor vaccine immunotherapy |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
